Incidence and medical costs of chronic obstructive respiratory disease in Spanish hospitals: a retrospective database analysis

References

• Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012; 379(9823):1341–1351.
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264–272.
   PubMed Web of Science ®Google Scholar
• Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–2242.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD). WHO; 2022. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed 20 Jun 2022.
   Google Scholar
• Miravitlles M, Sobradillo V, Villasante C, et al. Estudio epidemiológico de la EPOC en España (IBERPOC): reclutamiento y trabajo de campo [epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): recruitment and field work]. Arch Bronconeumol. 1999;35(4):152–158.
   PubMedGoogle Scholar
• Sobradillo V, Miravitlles M, Jiménez CA, et al. Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo [epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): prevalence of chronic respiratory symptoms and airflow limitation]. Arch Bronconeumol. 1999;35(4):159–166.
   PubMedGoogle Scholar
• Soriano JB, Ancochea J, Miravitlles M, et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997–2007. Eur Respir J. 2010;36(4):758–765.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Alfageme I, Miravitlles M, et al. Prevalence and determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol (Engl Ed). 2021;57(1):61–69.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–773.
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Calle M, Molina J, et al. Spanish COPD guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):69–81.
   PubMed Web of Science ®Google Scholar
• Recio Iglesias J, López García F, Almagro P, et al. Spanish clinical practice consensus in internal medicine on chronic obstructive pulmonary disease patients with comorbidities (miEPOC). Curr Med Res Opin. 2020;36(6):1033–1042.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Solé A, Aguilar H, et al. Economic impact of low adherence to COPD management guidelines in Spain. Int J Chron Obstruct Pulmon Dis. 2021;16:3131–3143.
   PubMed Web of Science ®Google Scholar
• Gutiérrez Villegas C, Paz-Zulueta M, Herrero-Montes M, et al. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. Health Econ Rev. 2021;11(1):31.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). CDC; 2022. https://www.cdc.gov/nchs/icd/icd-10-cm.htm. Accessed 10 May 2022.
   Google Scholar
• World Health Organization (WHO). International classification of primary care., 2nd edition (ICPC-2). WHO; 2022. https://www.who.int/standards/classifications/other-classifications/international-classification-of-primary-care. Accessed 10 May 2022.
   Google Scholar
• Law 14/2007 3rd July, on biomedical research (Boe, 4 July 2007). Rev Derecho Genoma Hum. 2007; (26):283–325. PMID: 18201045
   PubMedGoogle Scholar
• Montserrat-Capdevila J, Marsal JR, Ortega M, et al. Clinico-epidemiological characteristics of men and women with a new diagnosis of chronic obstructive pulmonary disease: a database (SIDIAP) study. BMC Pulm Med. 2021;21(1):44.
   PubMed Web of Science ®Google Scholar
• González J, Moncusí-Moix A, Benitez ID, et al. Clinical consequences of COVID-19 lockdown in patients with COPD: results of a pre-post study in Spain. Chest. 2021;160(1):135–138.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a european respiratory society/American thoracic society guideline. Eur Respir J. 2017;50(3):1602265.
   PubMed Web of Science ®Google Scholar
• Rehman AU, Ahmad Hassali MA, Muhammad SA, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):661–672.
   PubMed Web of Science ®Google Scholar
• Merino M, Villoro R, Hidalgo-Vega Á, et al. Social economic costs of COPD in extremadura (Spain): an observational study. Int J Chron Obstruct Pulmon Dis. 2018;13:2501–2514.
   PubMed Web of Science ®Google Scholar
• Sánchez-Muñoz G, Lopez-de-Andrés A, Hernández-Barrera V, et al. Bronchiectasis in patients hospitalized with acute exacerbation of COPD in Spain: influence on mortality, hospital stay, and hospital costs (2006–2014) according to gender. PLOS One. 2019;14(1):e0211222.
   PubMed Web of Science ®Google Scholar
• Landete P, Prieto Romo JI, Giacomini F. Experience on the management of patients with asthma or chronic obstructive pulmonary disease during the COVID-19 pandemic: the NEUMOBIAL study. Adv Ther. 2022;39(11):5216–5228.
   PubMed Web of Science ®Google Scholar
• de Miguel-Diez J, Lopez-de-Andres A, Jimenez-Garcia R, et al. Sex differences in COVID-19 hospitalization and hospital mortality among patients with COPD in Spain: a retrospective cohort study. Viruses. 2022;14(6):1238. Published 2022 Jun 7.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Celli BR. Patient related outcomes-BODE (PRO-BODE): a composite index incorporating health utilization resources predicts mortality and economic cost of COPD in real life. Respir Med. 2017;131:175–178.
   PubMed Web of Science ®Google Scholar